

## CLAIM LISTING

This listing of the claims replaces all prior versions, and listings, of claims in the application:

1. (Presently Amended) A method for treating an inflammation or lesion on a human or animal in need of said treatment, wherein said inflammation or lesion is caused by a virus, comprising contacting said inflammation or lesion with a virucidally effective amount of a composition consisting [[essentially]] of a pharmaceutically acceptable carrier and a synergistic combination, said synergistic combination consisting of a C1, a C2, or a C3 alcohol or a C2, C3, or C4 diol having a concentration of 0.2 to 12.5% by volume in water, and a sufficient amount of an acid to adjust the pH of the synergistic combination to between 2.45 and 4.6.
2. (Original) The method of claim 1, wherein said alcohol is selected from the group consisting of methanol, ethanol, 1-propanol, and 2-propanol.
3. (Original) The method of claim 1, wherein said alcohol is selected from the group consisting of 2,3-butanediol, 1,2-butanediol, 1,3-butanediol, and 1,4-butanediol.
4. (Original) The method of claim 2, wherein said alcohol is ethanol.
5. (Original) The method of claim 1, wherein said acid is an organic acid.
6. (Original) The method of claim 5, wherein said organic acid selected from the group consisting of glycolic acid, lactic acid, succinic acid, malic acid, citric acid and acetic acid.
7. (Original) The method of claim 1, wherein said acid is an inorganic acid.
8. (Original) The method of claim 7, wherein said acid is hydrochloric acid.
9. (Previously amended) The method of claim 1, wherein the pH of said

synergistic combination is 2.45.

10. Previously cancelled
11. (Original) The method of claim 1, wherein said virus resides in the dermis or epidermis of a human or animal infected by said virus.
12. (Original) The method of claim 1, wherein said composition is applied topically to reduce or inhibit lesions in an animal or human suffering from an infection by said virus.
13. (Original) The method of claim 1, wherein said virus is a member of the Herpesviridae family.
14. (Original) The method of claim 13, wherein said virus is herpes simplex 1.
15. (Original) The method of claim 13, wherein said virus is herpes simplex 2.
16. (Original) The method of claim 1, wherein said virus is Varicella-zoster virus.
17. (Original) The method of claim 1, wherein said virus is a member of the Poxviridae family.
18. (Original) The method of claim 17, wherein said virus is molluscum contagiosum.
19. (Original) The method of claim 1, wherein said virus is selected from the group consisting of rhinoviruses, adenoviruses, enteroviruses, coronavirus, respiratory syncytial viruses, influenza viruses and parainfluenza viruses.
20. (Original) The method of claim 1, wherein said composition is a preparation selected from the group consisting of a tincture, gel, ointment, cream, salve, lotion, lip balm, foam, spray and aerosol.

21. (Presently Amended) A method for treating an inflammation or lesion caused by a virus, comprising contacting said inflammation or lesion with a virucidally effective amount of a composition consisting [[essentially]] of a pharmaceutically acceptable carrier and a synergistic combination, said synergistic combination consisting of an alcohol selected from the group consisting of methanol, ethanol, 1-propanol, 2-propanol, 2,3-butanediol, 1,2-butanediol, 1,3-butanediol, and 1,4-butanediol having a concentration of 0.2 to 13.0% by volume in water, and a sufficient amount of an acid to adjust the pH of the synergistic combination to between 2.45 and 4.6, wherein said acid selected from the group consisting of glycolic acid, lactic acid, succinic acid, malic acid, citric acid, acetic acid, and hydrochloric acid.
22. (Previously amended) The method of claim 21, wherein the pH of said synergistic combination is 2.45.
23. Previously cancelled
24. (Previously Amended) The method of claim 21, wherein said composition is applied topically to reduce or inhibit lesions in said animal or human.
25. (Previously Amended) The method of claim 21, wherein said virus resides in the dermis or epidermis of said human or animal.
26. (Original) The method of claim 21, wherein said virus is a member of the Herpesviridae family.
27. (Original) The method of claim 26, wherein said virus is herpes simplex 1.
28. (Original) The method of claim 26, wherein said virus is herpes simplex 2.
29. (Original) The method of claim 26, wherein said virus is Varicella-zoster virus.

30. (Original) The method of claim 21, wherein said virus is a member of the Poxviridae family.
31. (Original) The method of claim 30, wherein said virus is molluscum contagiosum.
32. (Original) The method of claim 21, wherein said virus is selected from the group consisting of rhinoviruses, adenoviruses, enteroviruses, cornoviruses, respiratory syncytial viruses, influenza viruses and parainfluenza viruses.
33. (Original) The method of claim 21, wherein said composition is a topical preparation selected from the group consisting of a tincture, gel, ointment, cream, salve, lotion, lip balm, foam, spray and aerosol.
34. (Presently amended) A method for treating an inflammation or lesion caused by herpesvirus, comprising topically applying to said inflammation or lesion a composition consisting of a pharmaceutically acceptable carrier and a synergistic combination, said synergistic combination consisting of 10% by volume ethanol and 0.6% by weight glycolic acid, wherein the pH of the synergistic combination is about 2.45.